BioMarin (BMRN) Reports Q2 Earnings: What Key Metrics Have to SayZacks Investment Research • 08/05/24
BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 GuidancePRNewsWire • 08/05/24
BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and ItalyPRNewsWire • 08/05/24
Wall Street's Insights Into Key Metrics Ahead of BioMarin (BMRN) Q2 EarningsZacks Investment Research • 07/31/24
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 DiseasePRNewsWire • 07/24/24
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ETPRNewsWire • 07/23/24
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/22/24
Is The Options Market Predicting A Spike In BioMarin Pharmaceutical (BMRN) Stock?Zacks Investment Research • 07/15/24
BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone HealthPRNewsWire • 06/17/24
BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 CongressPRNewsWire • 06/07/24
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NVPRNewsWire • 05/08/24
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual MeetingPRNewsWire • 05/04/24